SMC publishes a Collaborative Advice Document for molnupiravir for COVID-19

The Scottish Medicines Consortium (SMC) collaborated with the National Institute for Health and Care Excellence (NICE) on TA1056: molnupiravir for treating COVID-19. 

SMC has published a Collaborative Advice Document for molnupiravir for treating COVID-19.  The recommendations are aligned with the NICE guidance for TA1056: molnupiravir for treating COVID-19.

Molnupiravir (Lagevrio®) is accepted for restricted use in NHSScotland for treatment of mild to moderate COVID-19 in specific patient groups.

A budget impact template is provided in confidence to NHS boards to enable them to estimate the predicted budget for medicines accepted for restricted use.

You can find the NICE final guidance here: Overview | Molnupiravir for treating COVID-19 | Guidance | NICE